Nanjing Bioheng Biotech Co., Ltd.
Clinical trials sponsored by Nanjing Bioheng Biotech Co., Ltd., explained in plain language.
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm overactive immune responses in people with autoimmune diseases like lupus, vasculitis, and scleroderma. The main goal is to check safety and …
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
Immune reset: CAR-T therapy targets lupus and other autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty immune cells causing autoimmune diseases like lupus and scleroderma. The goal is to see if this 'reset' is safe and can control disease activity. About 20 adults…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:52 UTC
-
Engineered immune cells take aim at lupus and MS
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and calm overactive immune responses in autoimmune diseases like lupus, scleroderma, and multiple sclerosis. The main goal is to check safety and how the body h…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:42 UTC